{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:18:44Z","timestamp":1787951924695,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC24H1270"],"award-info":[{"award-number":["NCC24H1270"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC2442680"],"award-info":[{"award-number":["NCC2442680"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijgc.2025.102756","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T14:44:13Z","timestamp":1761403453000},"page":"102756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"Ji Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-2657","authenticated-orcid":false,"given":"Eun Taeg","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uisuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4404-6000","authenticated-orcid":false,"given":"Sholanki","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3105-8913","authenticated-orcid":false,"given":"Dennis","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.102756_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102756_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3802\/jgo.2013.24.4.298","article-title":"Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010","volume":"24","author":"Lim","year":"2013","journal-title":"J Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102756_bib3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102756_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ijgc.2025.102756_bib5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102756_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102756_bib7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","article-title":"Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.ijgc.2025.102756_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102756_bib9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102756_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae insights: ovarian cancer\/Fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102756_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"7","key":"10.1016\/j.ijgc.2025.102756_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijgc.2025.102756_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1435","article-title":"Meta-analyses: what is heterogeneity?","volume":"350","author":"Sedgwick","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102756_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijgc.2025.102756_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102756_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"15","key":"10.1016\/j.ijgc.2025.102756_bib17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102756_bib18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for cancer: a trigger for metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102756_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/bies.20381","article-title":"Cancer surgery: risks and opportunities","volume":"28","author":"Coffey","year":"2006","journal-title":"BioEssays"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102756_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/0008-5472.CAN-15-1591","article-title":"Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress","volume":"76","author":"Tohme","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102756_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ctm2.24","article-title":"Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies","volume":"10","author":"Tang","year":"2020","journal-title":"Clin Transl Med"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102756_bib22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102756_bib23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102756_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2020.05.681","article-title":"Immunotherapy for platinum-resistant ovarian cancer","volume":"158","author":"Bogani","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102756_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2019.07.008","article-title":"Extending the platinum-free interval: the impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer","volume":"155","author":"Dockery","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102756_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102756_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FRalpha-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102756_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12885-019-5514-7","article-title":"Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)","volume":"19","author":"Chung","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102756_bib29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jogc.2020.04.008","article-title":"Response to multi-line chemotherapy in non-serous epithelial ovarian cancer","volume":"42","author":"Altman","year":"2020","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102756_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102756_bib31","first-page":"167","article-title":"Tumour hypoxia in driving genomic instability and tumour evolution","volume":"25","author":"Suvac","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102756_bib32","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e63","article-title":"Addendum: a phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study","volume":"33","author":"Shi","year":"2022","journal-title":"J Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:36:18Z","timestamp":1787949378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25018766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1048891X25018766"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102756","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102756"}}